Full Press Release Details
Marker Therapeutics Reports Third Quarter
2020 Operating and Financial Results
first Marker-sponsored study, a Phase 2 trial of MT-401 for the treatment of post-transplant acute myeloid leukemia, and
enrolled the first patient in the safety lead-in portion -
- Received alternate reagent and expect to submit required data to enable removal of partial clinical hold for IND for MT-401 by Q1 2021 -
host conference call and webcast today at 5:00 PM EST -
Houston, TX-November 9, 2020-Marker Therapeutics,
Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based
immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update
and reported financial results for the third quarter ended September 30, 2020.
"This quarter, our Company reached a significant milestone
by initiating our first Marker-sponsored study-a Phase 2 trial of zelenoleucel or MT-401, our lead MultiTAA-specific T cell
product candidate for the treatment of post-transplant acute myeloid leukemia," said Peter L. Hoang, President & CEO
of Marker Therapeutics. "We have enrolled the first patient in the safety lead-in portion of the trial, and are in the process
of scheduling the donor in order to manufacture the product."
Continued Mr. Hoang: "During this unprecedented time,
we have made significant progress by enrolling additional clinical sites for our AML trial, advancing our manufacturing process,
reducing production time by 50% and improving the potency of our MT-401 product, and entering the final phase of the construction
of our new in-house cGMP manufacturing facility. I am extremely proud of the dedication and resolve that our team has shown during
these challenging months. I want to acknowledge their hard work across the organization that went into achieving these milestones."
MT-401: Multi-Antigen Targeted (MultiTAA)-Specific T Cell
Product Candidate for AML
The Company initiated the safety lead-in portion of its Phase
2 study of zelenoleucel (MT-401) in patients with acute myeloid leukemia (AML) following an allogeneic stem cell transplant in
both the adjuvant and active disease settings. The Company anticipates treating the first patient by Q1 2021. The safety lead-in
is expected to enroll a total of six patients: three of which will be treated with MT-401 manufactured with a legacy reagent, and
the remaining three to be treated with study drug manufactured with a new reagent from an alternate supplier.
Marker has activated four clinical sites and is in the start-up
phase with additional clinical sites to enroll patients for the safety lead-in portion of the AML trial. The Company has also received
commitments from additional clinical sites to participate in the Phase 2 AML trial following the safety lead-in phase and anticipates
activating a total of approximately 20 sites.
The study remains on partial clinical hold pending the review
of final data and subsequent acceptance of certificates of analysis for the new reagent by the U.S. FDA. The Company received the
remaining reagent from the alternate supplier in Q3 2020 and is currently conducting the comparability analyses between the previous
and new reagents, as required by FDA. Marker intends to submit all required data to FDA by Q1 2021 to enable removal of the partial
Over the past year, the Company has continued to streamline
and simplify the MT-401 manufacturing process. The technical improvements include a 50% reduction in manufacturing time, a 95%
reduction in the number of required operator interventions, and significant improvement in the consistency and reproducibility
of the manufacturing process, while yielding a significant increase in the number of T cells available for patient administration.
The Company expects the new process to yield a measurably improved product, with superior T cell phenotype and antigen specificity
as compared to the original process. The new process improvements have been updated in the CMC section of the IND and will be used
for all patients in the Marker AML clinical trial.
THIRD QUARTER 2020 FINANCIAL RESULTS
Cash Position and Guidance: At September 30, 2020,
Marker had cash and cash equivalents of $27.0 million. The Company raised $2.2 million through the previously executed $30 million
common stock purchase agreement with Aspire Capital Fund, LLC. The remaining $27.8 million available to Marker from Aspire Capital
along with current cash available, funds operations into Q1 2022.
R&D Expenses: Research and development expenses
were $4.8 million for the quarter ended September 30, 2020, compared to $3.1 million for the quarter ended September
G&A Expenses: General and administrative expenses
were $2.6 million for the quarter ended September 30, 2020, compared to $2.5 million for the quarter ended September
Net Loss: Marker reported a net loss of $7.4
million for the quarter ended September 30, 2020, compared to a net loss of $5.5 million for the quarter ended September
Conference Call and Webcast
The Company will host a webcast and conference call to discuss
its third quarter 2020 financial results and provide a corporate update today at 5:00 PM EST.
The webcast will be accessible in the Investors section
of the Company's website at markertherapeutics.com. Individuals can participate in the conference call by dialing 877-407-8913
(domestic) or 201-689-8201 (international) and referring to the "Marker Therapeutics Third Quarter 2020 Earnings Call."
The archived webcast will be available for replay on the Marker
website following the event.
About Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology
company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies
and solid tumor indications. Marker's cell therapy technology is based on the selective expansion of non-engineered, tumor-specific
T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. This population
of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient's immune
system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cell therapies, we believe
that our product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered
CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio
of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies.
To receive future press releases via email, please visit: https://www.markertherapeutics.com/email-alerts
Forward-Looking Statement Disclaimer
This release contains forward-looking
statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this
news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements
concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking
statements." Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses
or current expectations concerning, among other things: our research, development and regulatory activities and expectations relating
to our non-engineered multi-tumor antigen specific T cell therapies; the effectiveness of these programs or the possible range
of application and potential curative effects and safety in the treatment of diseases; the impact of the COVID-19 pandemic; the
timing, conduct and success of our clinical trials, as well as clinical trials conducted by our collaborators; our manufacturing
processes and our ability to use our in-house manufacturing facility to support clinical and commercial demand. Forward-looking
statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially
from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth
in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at www.sec.gov. Such
risks and uncertainties may be amplified by the COVID-19 pandemic and its impact on our business and the global economy. The Company
assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise,
after the date of this press release.
Marker Therapeutics, Inc.
Condensed Consolidated Balance Sheets
| September 30, | December 31, | |||||||
| 2020 | 2019 | |||||||
| (Unaudited) | (Audited) | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 26,956,737 | $ | 43,903,949 | ||||
| Prepaid expenses and deposits | 2,367,145 | 1,526,442 | ||||||
| Interest receivable | 135 | 56,189 | ||||||
| Other receivable | 1,000,000 | - | ||||||
| Total current assets | 30,324,017 | 45,486,580 | ||||||
| Non-current assets: | ||||||||
| Property, plant and equipment, net | 2,629,628 | 417,528 | ||||||
| Construction in progress | 4,557,581 | - | ||||||
| Right-of-use assets, net | 11,059,962 | 455,174 | ||||||
| Total non-current assets | 18,247,171 | 872,702 | ||||||
| Total assets | $ | 48,571,188 | $ | 46,359,282 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable and accrued liabilities | $ | 5,746,149 | $ | 1,757,680 | ||||
| Lease liability | 278,333 | 204,132 | ||||||
| Warrant liability | - | 31,000 | ||||||
| Total current liabilities | 6,024,482 | 1,992,812 | ||||||
| Non-current liabilities: | ||||||||
| Lease liability, net of current portion | 11,948,781 | 280,247 | ||||||
| Total non-current liabilities | 11,948,781 | 280,247 | ||||||
| Total liabilities | 17,973,263 | 2,273,059 | ||||||
| Commitments and contingencies | - | - | ||||||
| Stockholders' equity: | ||||||||
| Preferred stock - $0.001 par value, 5 million shares authorized and 0 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively | - | - | ||||||
| Common stock, $0.001 par value, 150 million shares authorized, 48.0 million and 45.7 million shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively | 48,025 | 45,728 | ||||||
| Additional paid-in capital | 378,282,157 | 371,573,909 | ||||||
| Accumulated deficit | (347,732,257 | ) | (327,533,414 | ) | ||||
| Total stockholders' equity | 30,597,925 | 44,086,223 | ||||||
| Total liabilities and stockholders' equity | $ | 48,571,188 | $ | 46,359,282 |
Marker Therapeutics, Inc.
Condensed Consolidated Statements of
| For the Three Months Ended | For the Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2020 | 2019 | 2020 | 2019 | |||||||||||||
| Revenues: | ||||||||||||||||
| Grant income | $ | - | $ | - | $ | 466,785 | $ | - | ||||||||
| Total revenues | - | - | 466,785 | - | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 4,803,605 | 3,118,530 | 12,897,275 | 9,103,670 | ||||||||||||
| General and administrative | 2,572,562 | 2,536,204 | 7,946,846 | 8,063,099 | ||||||||||||
| Total operating expenses | 7,376,167 | 5,654,734 | 20,844,121 | 17,166,769 | ||||||||||||
| Loss from operations | (7,376,167 | ) | (5,654,734 | ) | (20,377,336 | ) | (17,166,769 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Change in fair value of warrant liabilities | - | (64,000 | ) | 31,000 | (80,000 | ) | ||||||||||
| Interest income | 4,667 | 259,248 | 147,493 | 897,967 | ||||||||||||
| Net loss | $ | (7,371,500 | ) | $ | (5,459,486 | ) | $ | (20,198,843 | ) | $ | (16,348,802 | ) | ||||
| Net loss per share, basic and diluted | $ | (0.16 | ) | $ | (0.12 | ) | $ | (0.43 | ) | $ | (0.36 | ) | ||||
| Weighted average number of common shares outstanding | 46,867,119 | 45,655,387 | 46,509,391 | 45,541,434 |
Marker Therapeutics, Inc.
Condensed Consolidated Statements of
| For the Nine Months Ended | ||||||||
| September 30, | ||||||||
| 2020 | 2019 | |||||||
| Cash Flows from Operating Activities: | ||||||||
| Net loss | $ | (20,198,843 | ) | $ | (16,348,802 | ) | ||
| Reconciliation of net loss to net cash used in operating activities: | ||||||||
| Depreciation and amortization | 272,725 | 70,908 | ||||||
| Changes in fair value of warrant liabilities | (31,000 | ) | 80,000 | |||||
| Stock-based compensation | 3,974,536 | 4,073,505 | ||||||
| Amortization on right-of-use assets | 337,530 | 134,919 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Prepaid expenses and deposits | (840,703 | ) | (1,764,345 | ) | ||||
| Interest receivable | 56,054 | 30,032 | ||||||
| Accounts payable and accrued expenses | 3,955,609 | 137,161 | ||||||
| Lease liability | (166,723 | ) | (136,812 | ) | ||||
| Net cash used in operating activities | (12,640,815 | ) | (13,723,434 | ) | ||||
| Cash Flows from Investing Activities: | ||||||||
| Purchase of property and equipment | (2,484,825 | ) | (362,121 | ) | ||||
| Purchase of construction in progress | (4,557,581 | ) | - | |||||
| Net cash used in investing activities | (7,042,406 | ) | (362,121 | ) | ||||
| Cash Flows from Financing Activities: | ||||||||
| Proceeds from issuance of common stock | 2,186,009 | - | ||||||
| Proceeds from exercise of stock options | - | 57,744 | ||||||
| Proceeds from exercise of warrants | 550,000 | 758,733 | ||||||
| Net cash provided by financing activities | 2,736,009 | 816,477 | ||||||
| Net decrease in cash | (16,947,212 | ) | (13,269,078 | ) | ||||
| Cash and cash equivalents at beginning of the period | 43,903,949 | 61,746,748 | ||||||
| Cash and cash equivalents at end of the period | $ | 26,956,737 | $ | 48,477,670 |